D. Kaufman

发表

Bladder-Conserving Therapy for Invasive Bladder Cancer Using Transurethral Surgery, Chemotherapy, and Radiation Therapy with Patient Selection by Initial Treatment Response

A. Zietman, W. Shipley, A. Althausen, 1998 .

Case records of the Massachusetts General Hospital. Case 6-2006. A 71-year-old woman with urinary incontinence and a mass in the bladder.

M. Harisinghani, P. Ryan, D. Kaufman, 2006, The New England journal of medicine.

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.

J. Richie, P. Kantoff, W. Oh, 2001, Seminars in oncology.

Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 2002, Urology.

The value of external beam radiation in node positive prostate cancer

A. Zietman, W. Shipley, A. Althausen, 2001 .

Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.

A. Niemierko, A. Zietman, J. Efstathiou, 2012, European urology.

Time-dose considerations in the treatment of anal cancer.

C. Willett, T. Delaney, C. Fung, 1997, International journal of radiation oncology, biology, physics.

Postoperative radiation therapy for high-risk colon carcinoma.

C. Willett, C. Fung, C. Fung, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer.

C. Willett, P. Shellito, D. Kaufman, 1998, Annals of surgery.

Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer.

A. Zietman, W. Mcdougal, R. Young, 2007, The New England journal of medicine.

Neoadjuvant Doxil Chemotherapy Prior to Androgen Ablation Plus Radiotherapy for High-Risk Localized Prostate Cancer: Feasibility and Toxicity

J. Manola, P. Kantoff, I. Kaplan, 2003, American journal of clinical oncology.

Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy.

W. Shipley, C. Fung, R. Young, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.

A. Zietman, W. Shipley, R. Young, 2001, Urology.

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03.

B. Donnelly, W. Shipley, C. Perez, 1998, The Journal of urology.

Bladder-sparing approaches to invasive disease

A. Zietman, J. Efstathiou, W. Shipley, 2006, World Journal of Urology.

Overview of bladder cancer trials in the Radiation Therapy Oncology Group

H. Sandler, W. Shipley, W. Tester, 2003, Cancer.

Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer.

M. Barry, Chin-Lee Wu, D. Kaufman, 2008, The New England journal of medicine.

Bladder cancer.Advances in laboratory innovations and clinical management, with emphasis on innovations allowing bladder‐sparing approaches for patients with invasive tumors

W. Shipley, G. Prout, D. Kaufman, 1990, Cancer.

Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer.

M. Harisinghani, A. Zietman, Chin-Lee Wu, 2011, The New England journal of medicine.

Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.

M. Michaelson, Richard J Lee, P. Saylor, 2010, The Journal of urology.

Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.

J. Efstathiou, W. Shipley, W. Mcdougal, 2012, The Journal of urology.

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

P. Kantoff, M. Michaelson, J. Finkelstein, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer.

A. Zietman, W. Shipley, J. Coen, 2007, Urologic oncology.

An organ-preserving approach to muscle-invading transitional cell cancer of the bladder.

A. Zietman, W. Shipley, A. L. Brown, 2001, Hematology/oncology clinics of North America.

Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 1997, Seminars in surgical oncology.

Bladder preservation by combined modality therapy for invasive bladder cancer.

A. Zietman, W. Shipley, L. Kachnic, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selective bladder preservation by combination treatment of invasive bladder cancer.

W. Shipley, A. Althausen, N. Heney, 1993, The New England journal of medicine.

The combination of cis-platin based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder.

A. Zietman, W. Shipley, D. Kaufman, 1993, International journal of radiation oncology, biology, physics.

Adjuvant Postoperative Radiation Therapy For Rectal Adenocarcinoma

C. Willett, J. Tepper, W. Wood, 1992, American journal of clinical oncology.

Bladder preservation: optimizing radiotherapy and integrated treatment strategies

R. Mak, A. Zietman, W. Shipley, 2008, BJU international.

Challenges in the treatment of bladder cancer.

D. Kaufman, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.

A. Zietman, H. Sandler, W. Shipley, 2005, Seminars in radiation oncology.

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.

W. Oh, M. Carducci, T. Kuzel, 2004, Urologic oncology.

Original article A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

W. Oh, M. Carducci, T. Kuzel, 2004 .

Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation.

A. Zietman, W. Shipley, A. Althausen, 1997, International journal of radiation oncology, biology, physics.

A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 1998, The Journal of urology.

A PHASE MI TRIAL OF TRANSURETHRAL SURGERY COMBINED WITH RADIATION FOLLOWED BY SELECTIVE BLADDER PRESERVATION IN OPERABLE PATIENTS WITH MUSCLE INVADING BLADDER CANCER CONCURRENT CISPLATIN, 5-FLUOROURACIL AND TWICE DAILY

A. Zietman, W. Shipley, A. Althausen, 1998 .

Opportunities with combined modality therapy for selective organ preservation in muscle‐invasive bladder cancer

A. Zietman, W. Shipley, A. Althausen, 1996, Journal of surgical oncology.

Interval report of a phase I-II study utilizing multiple modalities in the treatment of invasive bladder cancer. A bladder-sparing trial.

W. Shipley, G. Prout, N. Heney, 1991, The Urologic clinics of North America.

Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.

W. Shipley, A. Althausen, G. Prout, 1990, The Journal of urology.

L. True, B. Donnelly, W. Shipley, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trimodality therapy in the management of muscle-invasive bladder cancer: a selective organ-preserving approach

A. Zietman, W. Shipley, A. Althausen, 2008 .

An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.

A. Zietman, W. Shipley, A. Althausen, 1999, The Journal of urology.

Vinorelbine and estramustine in androgen‐independent metastatic prostate cancer

J. Manola, P. Kantoff, W. Oh, 2000, Cancer.

Case records of the Massachusetts General Hospital. Case 6-2007. A 28-year-old man with a mass in the testis.

M. Saksena, S. Tabatabaei, R. Young, 2007, The New England journal of medicine.

The Management and Outcome of Stage IA sub E Nonhodgkin's Lymphoma of the Testis

A. Zietman, R. Scully, J. Coen, 1996 .

Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer

A. Zietman, J. Efstathiou, W. Shipley, 2013, Current Urology Reports.

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

J. Manola, P. Kantoff, I. Kaplan, 2003, Urology.

Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.

A. Zietman, W. Shipley, M. Katz, 2006, Urology.

Selective aromatase inhibition for patients with androgen‐independent prostate carcinoma

J. Manola, P. Kantoff, W. Oh, 2002, Cancer.

The management and outcome of stage IAE nonHodgkin's lymphoma of the testis.

A. Zietman, R. Scully, J. Coen, 1996, The Journal of urology.

Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy.

R. Colvin, S. Schwartz, W. Shipley, 1992, The Journal of urology.

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder

M. Michaelson, A. Zietman, W. Shipley, 2004, British Journal of Cancer.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2004. A 57-year-old man with invasive transitional-cell carcinoma of the bladder.

W. Shipley, W. Mcdougal, R. Young, 2004, The New England journal of medicine.

An Update of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer

A. Zietman, W. Shipley, A. Althausen, 1998, European Urology.

Can chemo-radiotherapy plus transurethral tumor resection make cystectomy unnecessary for invasive bladder cancer?

W. Shipley, N. Heney, D. Kaufman, 1990, Oncology.

RTOG 9706: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapy

John D. Roberts, Christopher U. Jones, W. Shipley, 2001 .

Selective bladder preservation by combined modality treatment of invasive bladder cancer: 10-Year outcome

A. Zietman, W. Shipley, N. Heney, 2001 .

Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.

A. Gown, E. Oliva, M. Amin, 2013, Human pathology.

Phase II Trial of the Antiestrogen Toremifene for Androgen‐Independent Prostate Cancer

J. Manola, P. Kantoff, W. Oh, 1999 .

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

B. Spiegelman, P. Kantoff, G. Demetri, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Bladder cancer

W. Shipley, William U Shipley, D. Kaufman, 2009, The Lancet.

Phase II study of sunitinib in men with advanced prostate cancer.

P. Kantoff, M. Michaelson, W. Oh, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy

Eric Small, Daniel George, B. Spiegelman, 2004, Cancer.

Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors.

A. Zietman, W. Shipley, Jack Clark, 2003, The Journal of urology.

A Phase II Trial of Interferon-Alpha and Toremifene in Advanced Renal Cell Cancer Patients

J. Manola, P. Kantoff, C. Shapiro, 2002, Cancer investigation.

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

P. Kantoff, S. Larson, H. Scher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Male Patients with Diagnoses of Both Breast Cancer and Prostate Cancer

M. Loda, P. Kantoff, W. Oh, 2003, The breast journal.

Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer.

A. Zietman, W. Shipley, A. Althausen, 1996, Seminars in oncology.

Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.

A. Zietman, H. Sandler, R. Uzzo, 2014, International journal of radiation oncology, biology, physics.

Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy O

D. Grignon, H. Sandler, Chin-Lee Wu, 2005, International journal of radiation oncology, biology, physics.

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

R. Mak, A. Zietman, J. Efstathiou, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The integration of chemotherapy, radiotherapy and transurethral surgery in bladder-sparing approaches for patients with invasive tumors.

W. Shipley, A. Althausen, G. Prout, 1990, Progress in clinical and biological research.

The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.

L. True, W. Sause, W. Shipley, 2000, The oncologist.

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.

W. Oh, M. Carducci, B. Murphy, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.

John D. Roberts, Christopher U. Jones, A. Zietman, 2003, International journal of radiation oncology, biology, physics.

Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

H. Sandler, K. Bae, J. Efstathiou, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radio-chemotherapy for invasive carcinoma of the bladder.

W. Shipley, A. Althausen, G. Prout, 1992, Frontiers of radiation therapy and oncology.

Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.

A. Zietman, B. Czito, W. Shipley, 2004, The Journal of urology.

Malignant lymphoma of the thyroid gland: a clinical and pathologic study of twenty cases.

N. Harris, C. Wang, D. Kaufman, 1985, Surgery.

A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

J. Manola, P. Kantoff, W. Oh, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

C. Obasaju, F. Kabbinavar, D. Vaughn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.

J. Manola, P. Kantoff, W. Oh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel, E stramustine P hosphate, a nd C arboplatin i n Patients W ith A dvanced P rostate C ancer

P. Kantoff, S. Larson, L. Schwartz, 2006 .

Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.

N. Agarwal, G. Sonpavde, M. Galsky, 2013, Clinical genitourinary cancer.

Radiotherapy and chemotherapy in invasive bladder cancer with potential bladder sparing.

W. Shipley, A. Althausen, D. Kaufman, 1992, Hematology/oncology clinics of North America.

Outcomes of Selective Bladder Preservation in the Elderly Treated With Conservative Surgery and Chemoradiation

A. Niemierko, A. Zietman, P. Gray, 2013 .

Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

A. Zietman, H. Sandler, R. Uzzo, 2013, The Lancet. Oncology.

The results of concurrent chemo‐radiotherapy for recurrence after treatment with bacillus Calmette‐Guérin for non‐muscle‐invasive bladder cancer: is immediate cystectomy always necessary?

A. Zietman, W. Shipley, N. Heney, 2009, BJU international.

Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

A. Zietman, H. Sandler, W. Shipley, 2009, Urology.

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer

P. Kantoff, M. Michaelson, W. Oh, 2006, Cancer.

Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.

Andrzej Niemierko, Anthony L Zietman, A. Niemierko, 2013, International journal of radiation oncology, biology, physics.

Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient.

A. Zietman, W. Shipley, L. Kachnic, 1996, The cancer journal from Scientific American.

Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy

A. Zietman, W. Shipley, D. Kaufman, 2000, Annals of medicine.

42 A phase trial of transurethral surgery plus cisplatin and radiation therapy followed by either selective bladder preservation or radical cystectomy for patients with muscle-invading bladder cancer but without hydronephrosis

A. Zietman, W. Shipley, A. Althausen, 1997 .

Case records of the Massachusetts General Hospital. Case 30-2009. A 77-year-old man with recurrent transitional-cell carcinoma of the ureter.

M. Harisinghani, Chin-Lee Wu, W. Mcdougal, 2009, The New England journal of medicine.

Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.

P. Febbo, J. Manola, P. Kantoff, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233.

R. Mak, A. Zietman, J. Efstathiou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgery: Selective bladder-preserving therapy for muscle-invasive cancer

W. Shipley, N. Heney, D. Kaufman, 2009, Nature Reviews Clinical Oncology.

Phase I I T rial o f G emcitabine P lus C isplatin i n P atients With M etastatic U rothelial C ancer

W. Oh, M. Carducci, B. Murphy, 2000 .

Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233.

R. Mak, A. Zietman, J. Efstathiou, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.

R. Weissleder, M. Harisinghani, A. Zietman, 2009, Clinical imaging.

Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy

A. Zietman, H. Sandler, R. Uzzo, 2010 .

Organ conservation as an alternative to radical cystectomy for invasive bladder cancer: urodynamic and quality of life evaluation of patients treated by trimodality therapy

A. Zietman, W. Shipley, A. Althausen, 2002 .

Improved outcome with escalated radiation dosing for anal carcinoma

C. Willett, C. Fung, P. Shellito, 1993 .

Long-term Outcomes After Bladder-Preserving Combined Modality Therapy for Patients With Muscle-Invasive Bladder Cancer

A. Niemierko, M. Michaelson, A. Zietman, 2015 .

Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer?

C. Willett, C. Fung, C. Fung, 1999, The cancer journal from Scientific American.

Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation.

C. Compton, C. Willett, A. Chakravarti, 1999, Annals of surgery.

308: An Update of Selective Bladder Preservation Using Combined Modality Treatment in Invasive Bladder Cancer: Long Term Outcome Reveals a Low Risk of Invasive Recurrence and a High Probability of Bladder Preservation

A. Zietman, W. Shipley, A. Althausen, 2004 .

Adjuvant Postoperative Radiation Therapy for Colonic Carcinoma.

S. Skates, C. Willett, J. Tepper, 1993, Seminars in radiation oncology.

Chemoradiotherapy for anal carcinoma: What is the optimal radiation dose?

C. Willett, C. Fung, P. Shellito, 1994 .

Fatal lymphoma after transplantation of cultured thymus in children with combined immunodeficiency disease.

M. Dictor, D. Kaufman, L. Pachman, 1979, The New England journal of medicine.

Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder.

M. Harisinghani, A. Zietman, Chin-Lee Wu, 2013, The New England journal of medicine.

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy.

M. Harisinghani, A. Zietman, W. Mcdougal, 2004, The New England journal of medicine.